MCL1 and cancer: Given the anti-apoptotic property of MCL-1, MCL-1 has been shown to be both an intrinsic and acquired resistance factor that impairs the potency of various antitumor agents, and studies have suggested the utility of cancer therapy targeting MCL-1 based on the anti-apoptotic property of MCL-1 [13].